SG59971A1 - Pyridazino quinoline compounds - Google Patents

Pyridazino quinoline compounds

Info

Publication number
SG59971A1
SG59971A1 SG1996007261A SG1996007261A SG59971A1 SG 59971 A1 SG59971 A1 SG 59971A1 SG 1996007261 A SG1996007261 A SG 1996007261A SG 1996007261 A SG1996007261 A SG 1996007261A SG 59971 A1 SG59971 A1 SG 59971A1
Authority
SG
Singapore
Prior art keywords
phenyl
deriv
substd
opt
furyl
Prior art date
Application number
SG1996007261A
Other languages
English (en)
Inventor
Thomas Michael Bare
Richard Bruce Sparks
James Roy Empfield
Timothy Wayne Davenport
Jeffrey Alan Mckinney
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939321854A external-priority patent/GB9321854D0/en
Priority claimed from GB9417171A external-priority patent/GB9417171D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of SG59971A1 publication Critical patent/SG59971A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
SG1996007261A 1993-10-22 1994-10-20 Pyridazino quinoline compounds SG59971A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321854A GB9321854D0 (en) 1993-10-22 1993-10-22 Pyridazino quinoline compounds
GB9417171A GB9417171D0 (en) 1994-08-25 1994-08-25 Pyridazino quinoline compounds

Publications (1)

Publication Number Publication Date
SG59971A1 true SG59971A1 (en) 1999-02-22

Family

ID=26303731

Family Applications (2)

Application Number Title Priority Date Filing Date
SG1996007261A SG59971A1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds
SG9900943A SG92630A1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG9900943A SG92630A1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds

Country Status (29)

Country Link
US (3) US5744471A (cs)
EP (2) EP0724583B1 (cs)
JP (1) JP3583132B2 (cs)
KR (1) KR100261209B1 (cs)
CN (1) CN1053189C (cs)
AT (2) ATE198072T1 (cs)
AU (2) AU688393B2 (cs)
CA (1) CA2171332A1 (cs)
CZ (1) CZ292311B6 (cs)
DE (2) DE69426422T2 (cs)
DK (2) DK0724583T3 (cs)
ES (2) ES2241513T3 (cs)
FI (2) FI113865B (cs)
GB (1) GB9420590D0 (cs)
GR (1) GR3035080T3 (cs)
HU (1) HUT74161A (cs)
IL (1) IL111266A (cs)
MY (2) MY132875A (cs)
NO (1) NO306995B1 (cs)
NZ (2) NZ329303A (cs)
PL (1) PL180679B1 (cs)
PT (2) PT1004582E (cs)
RU (1) RU2168511C2 (cs)
SG (2) SG59971A1 (cs)
SI (2) SI0724583T1 (cs)
SK (1) SK282491B6 (cs)
TW (1) TW406082B (cs)
UA (1) UA60291C2 (cs)
WO (1) WO1995011244A1 (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
US6214826B1 (en) 1994-11-12 2001-04-10 Zeneca Limited Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
WO2001047523A1 (en) * 1999-12-23 2001-07-05 Astrazeneca Ab Method and composition for the treatment of pain
US6730675B2 (en) 1999-12-23 2004-05-04 Astrazeneca Ab Compounds and methods for the treatment of pain
AU2566201A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Compounds and methods for the treatment of pain
JP2003519148A (ja) * 1999-12-23 2003-06-17 アストラゼネカ・アクチエボラーグ 痛みの処置のための化合物および方法
US6943165B2 (en) * 1999-12-23 2005-09-13 Astrazeneca Ab Compound and method for the treatment of pain
AU2566101A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Compounds and methods for the treatment of pain
WO2001047924A1 (en) * 1999-12-23 2001-07-05 Astrazeneca Ab Methods and compositions for the treatment of pain
WO2001047927A1 (en) * 1999-12-23 2001-07-05 Astrazeneca Ab Compound and method for the treatment of pain
US6787547B2 (en) 1999-12-23 2004-09-07 Astrazeneca Ab Compound and method for the treatment of pain
SI1244662T1 (cs) * 1999-12-23 2005-08-31 Astrazeneca Ab
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
AU2420101A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Method and composition for the treatment of pain
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
ATE327235T1 (de) 2000-09-29 2006-06-15 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino 4,5-böchinolin-1, 0-dione und ihre anwendung in der behandlung von schmerzen
WO2002026741A1 (en) * 2000-09-29 2002-04-04 Astrazeneca Ab 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN
WO2002026740A1 (en) * 2000-09-29 2002-04-04 Astrazeneca Ab 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain
JP2004509963A (ja) * 2000-09-29 2004-04-02 アストラゼネカ・アクチエボラーグ 1,2,5,10−テトラヒドロピリダジノ[4,5−b]キノリン−1,10−ジオン及び疼痛治療のためのその使用
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CA2448561C (en) * 2001-05-31 2011-07-19 Sanofi-Synthelabo Aminoquinoline derivatives and their use as adenosine a3 ligands
AU2003301513A1 (en) 2003-08-04 2005-02-15 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
EP2532650A3 (en) 2004-06-24 2013-11-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2007075901A2 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
NO2821400T3 (cs) 2009-03-20 2018-02-24
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US20130224293A1 (en) 2012-02-27 2013-08-29 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814458D0 (en) * 1988-06-17 1988-07-20 Wyeth John & Brother Ltd Heterocyclic compounds
GB9109972D0 (en) * 1991-05-09 1991-07-03 Ici Plc Therapeutic compounds
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds

Also Published As

Publication number Publication date
KR100261209B1 (ko) 2000-09-01
ES2241513T3 (es) 2005-11-01
NO961584D0 (no) 1996-04-19
AU721139B2 (en) 2000-06-22
PT724583E (pt) 2001-03-30
IL111266A (en) 2002-03-10
HUT74161A (en) 1996-11-28
FI970907L (fi) 1997-03-03
CN1053189C (zh) 2000-06-07
DE69434380D1 (de) 2005-06-23
US5744471A (en) 1998-04-28
WO1995011244A1 (en) 1995-04-27
US6232313B1 (en) 2001-05-15
NZ329303A (en) 2000-01-28
CZ113896A3 (en) 1996-09-11
CZ292311B6 (cs) 2003-09-17
DE69426422T2 (de) 2001-05-10
EP0724583A1 (en) 1996-08-07
JP3583132B2 (ja) 2004-10-27
JPH09504519A (ja) 1997-05-06
SK282491B6 (sk) 2002-02-05
HK1013997A1 (en) 1999-09-17
PL314041A1 (en) 1996-08-05
EP0724583B1 (en) 2000-12-13
ATE198072T1 (de) 2000-12-15
ES2154686T3 (es) 2001-04-16
EP1004582A2 (en) 2000-05-31
EP1004582A3 (en) 2000-08-30
NZ275472A (en) 1998-03-25
FI961696A0 (fi) 1996-04-18
DK1004582T3 (da) 2005-08-15
UA60291C2 (uk) 2003-10-15
DK0724583T3 (da) 2001-03-05
CN1138332A (zh) 1996-12-18
EP1004582B1 (en) 2005-05-18
MY132875A (en) 2007-10-31
DE69434380T2 (de) 2006-05-04
US6103721A (en) 2000-08-15
HU9600889D0 (en) 1996-06-28
PL180679B1 (en) 2001-03-30
PT1004582E (pt) 2005-09-30
TW406082B (en) 2000-09-21
FI113865B (fi) 2004-06-30
FI961696L (fi) 1996-04-18
DE69426422D1 (de) 2001-01-18
MY124316A (en) 2006-06-30
CA2171332A1 (en) 1995-04-27
AU688393B2 (en) 1998-03-12
SK50496A3 (en) 1997-03-05
GR3035080T3 (en) 2001-03-30
FI114916B (fi) 2005-01-31
AU7944094A (en) 1995-05-08
AU6899998A (en) 1998-07-30
RU2168511C2 (ru) 2001-06-10
IL111266A0 (en) 1994-12-29
FI970907A0 (fi) 1997-03-03
NO306995B1 (no) 2000-01-24
SI1004582T1 (cs) 2005-08-31
ATE295846T1 (de) 2005-06-15
GB9420590D0 (en) 1994-11-30
NO961584L (no) 1996-04-19
SI0724583T1 (en) 2001-04-30
SG92630A1 (en) 2002-11-19

Similar Documents

Publication Publication Date Title
HU9600889D0 (en) Pyridazino quinoline compounds
TW370529B (en) Pyrazolopyrimidines
ATE206412T1 (de) Heterocyclische verbindungen als bradykinin antagonisten
DE69720965D1 (de) Chinazolinderivate und deren verwendung als vegf hemmer
EA199900927A1 (ru) Трициклические соединения
ES8600288A1 (es) Un procedimiento para la preparacion de derivados de quinolina.
HU9203002D0 (en) Method for producing tricyclic heterocyclic compounds
DE69207182D1 (en) Antitumor anthracenderivate
DE69316392D1 (de) Azanoradamantane
HU900728D0 (en) Process for preparation of calcium antagonistics
EA199800062A1 (ru) Новые гетероциклические соединения для лечения боли и их применение
FR2342063A2 (fr) Nouveaux acetamidoximes, leur procede de preparation et leur application en therapeutique
FI954340A7 (fi) Menetelmä uusien terapeuttisesti käytt¦kelpoisten 5-substituoitu tia-sykloalka-ÄdÜ-1,2,4-triatsoloÄ1,5-aÜpyrimidiinijohdannaisten valmistamiseksi